The global artificial insemination market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 8% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use sectors. These insights are included in the report as a major market contributor.
Artificial insemination is an assisted reproductive treatment wherein semen with living sperms is introduced into the cervix, fallopian tubes, or uterus of a female. It is performed via artificial insemination homologous (AIH) or artificial insemination donor semen (AID) procedures that are short and relatively painless. Self-insemination kits are nowadays available in the market that can be used at the convenience of home. At present, artificial insemination is widely being used in animal breeding to facilitate the reproductive success and conservation of threatened or endangered species. It also prevents the spread of certain diseases and sterility due to genital conditions in animals.
The rising infertility rates, along with the increasing awareness among individuals about alternative reproductive treatments, represent one of the significant factors influencing the market. Moreover, governments of numerous countries have legalized same-sex marriage and are providing insurance coverage to civil unions for artificial insemination procedures, which is also contributing to the market growth. Apart from this, the rising global population and the escalating demand for animal-based protein are fueling the need for artificial insemination among domestic livestock animals. Improving veterinary services and rising expenditure on animal healthcare is also supporting the market growth. Furthermore, the leading players are entering into strategic collaborations for expanding their portfolio of animal genetic and strengthening their position in different markets. For instance, Genus plc, which is a leading animal genetics company, partnered with Beijing Capital Agribusiness Co. Ltd, a leading Chinese animal protein genetics business, to research and develop virus-resistant techniques in pigs.
IMARC Group provides an analysis of the key trends in each sub-segment of the global artificial insemination market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, type, source type and end use.
Breakup by Type:
Breakup by Source Type:
Breakup by End Use:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Conceivex Inc., FUJIFILM Irvine Scientific Inc. (Fujifilm Holdings Corporation), Genea Limited, Genus plc, Hamilton Thorne Inc., Hi-Tech Solutions, Kitazato Corporation, Pride Angel, Rinovum Women’s Health LLC, Rocket Medical plc, TenderNeeds Fertility LLC and Vitrolife AB.
|Base Year of the Analysis||2020|
|Segment Coverage||Type, Source Type, End Use, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Conceivex Inc., FUJIFILM Irvine Scientific Inc. (Fujifilm Holdings Corporation), Genea Limited, Genus plc, Hamilton Thorne Inc., Hi-Tech Solutions, Kitazato Corporation, Pride Angel, Rinovum Women’s Health LLC, Rocket Medical plc, TenderNeeds Fertility LLC and Vitrolife AB.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at